Psych Vivas · General adult psychiatry — anxiety disorders
Social anxiety disorder — structured clinical viva
Fellowship viva covering chronic SAD, alcohol safety behaviour, inadequate prior SSRI trials, Clark/Wells CBT targets, and evidence-based medication including maintenance and specialist MAOI context.
On this page
Study tools
Target exams
Interpretation
Reveal interpretationShowHide
This is generalised social anxiety disorder (interactional and performance situations) with alcohol as a safety behaviour and inadequate prior antidepressant trials (stopped within 10 days — not therapeutic dose/duration). The belief "I already know I am awkward" is a treatment target (distorted self-image / certainty without behavioural experiments), not a reason to abandon CBT. Do not escalate long-term benzodiazepines as the primary plan.[1][4][5]
Formulation. Vulnerability (possible behavioural inhibition/temperament), maintaining factors (self-focused attention, safety behaviours including alcohol, post-event processing, avoidance of meetings), precipitants (workplace demands), and iatrogenic history of aborted SSRI trials without activation management.[1]
SSRI re-challenge strategy. Explain early activation; start low (e.g. sertraline 25 mg), frequent early review, short-term non-escalating support, parallel CBT engagement work. Prior "failure" at 10 days is not pharmacological non-response.[3][5]
CBT sales pitch without collusion. Validate distress; introduce experiments testing whether others notice blushing as much as feared; attention training; video feedback; drop alcohol-as-safety-behaviour experiments with medical support if dependence risk high.[1][4]
Specialist ladder. If true non-response after adequate SSRI/SNRI and quality CBT: switch class, combination, refractory pathway; phenelzine has landmark comparative efficacy versus CBGT but requires specialist MAOI counselling (diet, interactions, washout).[2][5]
Maintenance. After response, continue medication for a substantial period — sertraline continuation reduces relapse versus placebo substitution in responders.[6]
References6ShowHide
- [1]Stein MB, Stein DJ Social anxiety disorder Lancet, 2008.PMID 18374843
- [2]Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome Arch Gen Psychiatry, 1998.PMID 9862558
- [3]Van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia Am J Psychiatry, 2001.PMID 11156811
- [4]Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis Lancet Psychiatry, 2014.PMID 26361000
- [5]Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders BMC Psychiatry, 2014.PMID 25081580
- [6]Walker JR, Van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment J Clin Psychopharmacol, 2000.PMID 11106135